S. Glatt

发表

First‐in‐human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL‐17A and IL‐17F, in mild psoriasis

P. Vajjah, O. Harari, G. Price, 2017, British journal of clinical pharmacology.

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial

M. Moutschen, S. Tavernier, K. Vanhove, 2022, Respiratory Research.

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation

A. Lawson, Terry S Baker, P. Miossec, 2017, Annals of the rheumatic diseases.

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa

C. Zouboulis, S. Forman, D. Baeten, 2021, JAMA dermatology.

Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice.

Iñaki F Trocóniz, Sophie Glatt, J. Yingling, 2008, European journal of cancer.

A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models

Gordon Graham, Leon Aarons, Kayode Ogungbenro, 2007, Comput. Methods Programs Biomed..

Population Pharmacokinetics of Onercept in Healthy Subjects

E. Fuseau, Q. Nguyen, S. Glatt, 2005, Clinical pharmacokinetics.

First human dose escalation study in patients with metastatic malignancies to determine safety and pharmacokinetics of LY2157299, a small molecule inhibitor of the transforming growth factor-beta receptor I kinase

J. Baselga, M. Carducci, C. Arteaga, 2008 .

Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study

S. Garcet, B. Dizier, D. Baeten, 2021, The British journal of dermatology.

Characterization of a surrogate murine antibody to model anti-human CD3 therapies

W. Reith, L. Cons, Fabien Dépis, 2013, mAbs.

A cross‐species translational pharmacokinetic‐pharmacodynamic evaluation of core body temperature reduction by the TRPM8 blocker PF‐05105679

P. H. van der Graaf, K. Beaumont, W. Winchester, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Inhibition of TRPM8 Channels Reduces Pain in the Cold Pressor Test in Humans

M. Postlethwaite, M. Andrews, P. Saintot, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study

R. Landewé, G. Schett, I. McInnes, 2019, Annals of the rheumatic diseases.

Cold-Responsive Trigeminal Neurons From Rat TRPM8 mRNA Is Expressed in a Subset of

M. Postlethwaite, A. Dhaka, M. Caterina, 2015 .

Inhibition of TRPM8 Channels Reduces Pain in the Cold Pressor Test in Humans

M. Postlethwaite, M. Andrews, P. Saintot, 2014, The Journal of Pharmacology and Experimental Therapeutics.